Molecular Fluorescence Endoscopy of (Pre)Malignant Esophageal Lesions (EAGLE)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03205501|
Recruitment Status : Unknown
Verified December 2017 by dr. W.B. Nagengast, MD, University Medical Center Groningen.
Recruitment status was: Recruiting
First Posted : July 2, 2017
Last Update Posted : December 14, 2017
To improve detection of esophageal (pre)malignant lesions during surveillance endoscopy of patients at risk of developing malignancies, for example in Barrett's Esophagus (BE), there is a need for better endoscopic visualization and the ability for targeted biopsies. Optical molecular imaging of neoplasia associated biomarkers could form a promising technique to accommodate this need. It is known that the biomarker c-Met is overexpressed in dysplastic and neoplastic areas in BE segments versus normal tissue and has proven to be a valid target for molecular imaging.
Edinburgh Molecular Imaging Ltd (EMI) has developed a fluorescent tracer specifically targeting c-Met by labeling a small peptide to a fluorescent fluorophore: 'EMI-137'. The investigators hypothesize that when EMI-137 is administered intravenously, it accumulates in c-Met expressing high grade dysplasia (HGD) and esophageal adenocarcinoma (EAC), enabling (early) cancer visualization using a newly developed fluorescent fiber-bundle. This hypothesis will be tested in the current pilot intervention study.
|Condition or disease||Intervention/treatment||Phase|
|Barrett Esophagus Esophageal Cancer Dysplasia in Barrett Esophagus||Drug: IV-administation of EMI-137 Device: Molecular Fluorescence Endoscopy platform||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||25 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Molecular Fluorescence Endoscopy for the Detection of (Pre)Malignant Lesions in Barrett's Esophagus Using a Fluorescent Tracer 'EMI-137' Targeting c-Met: a Single-center Feasibility and Safety Study|
|Actual Study Start Date :||February 9, 2017|
|Estimated Primary Completion Date :||December 12, 2018|
|Estimated Study Completion Date :||December 12, 2018|
Experimental: IV-tracer EMI-137
Drug: IV-administation of EMI-137
Intravenous administration of 0.13 mg/kg of the fluorescent tracer EMI-137 approximately 2.5 hours prior to the endoscopy procedure.
Other Name: Tracer administation
Device: Molecular Fluorescence Endoscopy platform
A flexible fluorescence fiber-bundle is attached to a fluorescence camera platform to enable the detection of fluorescence signals. The fluorescence fiber-probe is inserted through the standard working-channel of the standard clinical endoscope. Fluorescence imaging will be performed prior to and post the endoscopic resection, during the same endoscopy procedure.
Other Name: Fluorescence Endoscopy
- Tumor-to-background ratio that allows the in vivo detection of (pre)malignant lesions in patients with Barrett's Esophagus using molecular fluorescence endoscopy. [ Time Frame: Day 1 ]Calculation of the in vivo tumor-to-background ratio (> 1.5) based on fluorescence intensities in (pre)malignant lesions compared to surrounding healthy esophageal tissue.
- Safety: the number of participants with symptoms or changes in vital signs (blood pressure, heart frequency and temperature) and/or (serious) adverse events that are related to administration of EMI-137. [ Time Frame: Up to day 3 ]
- The correlation of fluorescence signals to histopathology from (pre)malignant lesions and surrounding normal esophageal tissue. [ Time Frame: Up to 1 year ]
- Identification of fluorescence lesions and correlation with histopathology on subsequent biopsies in the resection surface after endoscopic mucosal resection. [ Time Frame: Up to 1 year ]
- Quantification of fluorescence signals in vivo and ex vivo of (pre)malignant lesions and normal esophageal tissue using multi-diameter single-fiber reflectance single-fiber fluorescence (MDSFR-SFF) spectroscopy. [ Time Frame: Up to 1 year ]
- Visualization of the localization and distribution patterns of EMI-137 in the esophagus using ex vivo fluorescence microscopy. [ Time Frame: Up to 1 year ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03205501
|Contact: W.B. Nagengast, MD, PhD, PharmDfirstname.lastname@example.org|
|Contact: S.J. de Jongh, MDemail@example.com|
|University Medical Center Groningen||Recruiting|
|Groningen, Netherlands, 9713GZ|
|Contact: W.B. Nagengast, MD, PhD, PharmD +31503612620 firstname.lastname@example.org|
|Contact: S.J. de Jongh, MD +31503613473 email@example.com|
|Principal Investigator: W.B. Nagengast, MD, PhD, PharmD|
|Principal Investigator: G.M. van Dam, MD, PhD|
|Principal Investigator:||W.B. Nagengast, MD, PhD, PharmD||University Medical Center Groningen|
|Principal Investigator:||G.M. van Dam, MD, PhD||University Medical Center Groningen|